Computerized Cognitive Assessment Products – Neurocognitive Screening for ADHD, Memory Loss, Alzheimer’s, Dementia, Traumatic Brain Injury Since our last report in 2011, the market for computerized cognitive assessment, screening and testing has continued to expand. Key drivers for this market and growing technology product base include: An Aging Global Population: 500 million people in the… Read More »
We thought it would be useful to provide an overview of the range of cognitive function tests available to screen for mild cognitive impairment (MCI) and early signs of Alzheimer’s and dementia. All of the tests mentioned in this article are backed up by published research studies that validate test use as a screening tool… Read More »
A recent initiative from the Congressional Brain Injury Task Force highlights an important issue affecting millions of Americans living with traumatic brain injury (TBI): the lack of long-term TBI rehabilitation care for most people, including those with health care insurance. A letter from the office of U.S. Rep. Gabrielle Giffords to HHS Secretary Kathleen Sebelius… Read More »
(Author note: This article refers to basic cognitive testing of workers by companies and employers. Personality tests, aptitude tests, IQ tests, integrity and other similar tests are outside the scope of this article.) The growing prevalence of computerized cognitive testing allows a wide range of employers and organizations to test large numbers of workers in… Read More »
Cognitive testing in primary care settings like a doctor’s office or community health clinic is still a rare occurrence. While some health care practices are beginning to take notice of the need for preventive cognitive screening for conditions like memory loss and mild cognitive impairment (which could be the early stages of Alzheimer’s), most medical… Read More »
Formal cognitive testing in pharmaceutical trials is relatively new. Up until 2000, most drug trial designs did not include any form of baseline and end point cognitive testing, even for drugs that act directly on the central nervous system (CNS). A significant push towards standardized cognitive assessments in clinical drug trials occurred in 2005 when… Read More »